Table 2.

Effect of SU11248 on freshly isolated acute leukemia cells

Patient no.Age/sexFABWBC (×109)%BlastGenetic abnormalitiesFLT3 mutationsIC50 (μmol/L)Disease status
180/MM17,900561Initial presentation
280/MM110,60025−7, −13, −16, −12, −21, add(8)(q24)0.8Initial presentation
359/MM11,30043-5, −7, −8, −13, −14, −16, add(17)(q23)Not achievedInitial presentation
472/FM246,90079ITD<0.01Initial presentation
580/MM15,80088−3, −7, −8, −17, −18, −21, −22, add(18)(p11)0.1Relapse
632/ML277,10054t(9;22)(q34;q11), add(8)(q24), add(7)(q34)1Relapse
755/MM284,70070ITD<0.01Relapse
845/MM16,10016t(6;9)(p23;q34), +8, +13ITD<0.01Relapse
944/FM47,100110.2Initial presentation
1069/MM428,10096+1, der(1;12)(q10;q10)Not achievedRelapse
1164/FM17,00047Not achievedInitial presentation
1274/MM15,20086del(16)(q?)Not achievedInitial presentation
1377/FM11,900140.9Initial presentation
1472/FM218,90094t(8;21)(q22;q22)ITD<0.01Relapse
1550/FM36,30089t(15;17)(q22;q12)D8350.01Initial presentation
1668/MM187,70096ITD<0.01Initial presentation
  • NOTE: The freshly isolated leukemia cells were cultured in the presence of various concentrations of SU11248 (0.01–l μmol/L). After 2 days, the proliferation of cells was measured by [3H]thymidine uptake. The IC50 of SU11248 was calculated from the dose-response curves.